CYP2A6 genotype but not age determines cotinine half-life in infants and children

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 3, 2013, Pages 400-406

  Dempsey, D A ^a,b   Sambol, N C ^a,b,c   Jacob, P ^a,b,c   Hoffmann, E ^d   Tyndale, R F ^d   Fuentes Afflick, E ^b   Benowitz, N L ^a,b,c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COTININE; CYTOCHROME P450 2A6; DEUTERIUM; DNA; CYP2A6 PROTEIN, HUMAN; PASSIVE SMOKING; UNSPECIFIC MONOOXYGENASE;

ALLELE; ARTICLE; CHILD; DRUG HALF LIFE; FEMALE; GENOTYPE; HUMAN; INFANT; MALE; PASSIVE SMOKING; PRESCHOOL CHILD; PRIORITY JOURNAL; SALIVA; URINALYSIS; AFRICAN AMERICAN; AGE; CAUCASIAN; GENETICS; HALF LIFE TIME; HISPANIC; METABOLISM; URINE;

AFRICAN AMERICANS; AGE FACTORS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHILD, PRESCHOOL; COTININE; CYTOCHROME P-450 CYP2A6; DEUTERIUM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HALF-LIFE; HISPANIC AMERICANS; HUMANS; INFANT; TOBACCO SMOKE POLLUTION;

EID: 84883143222     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.114     Document Type: Article

References (32)

1. Benowitz, N.L., Hukkanen, J. & Jacob, P. 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb. Exp. Pharmacol. 192, 29-60 (2009).
2. Benowitz, N.L. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol. Rev. 18, 188-204 (1996).
3. Dempsey, D.A. et al. Determination of tobacco smoke exposure by plasma cotinine levels in infants and children attending urban public hospital clinics. Arch. Pediatr. Adolesc. Med. 166, 851-856 (2012).
4. Cornelius, M.D., Goldschmidt, L. & Dempsey, D.A. Environmental tobacco smoke exposure in low-income 6-year-olds: parent report and urine cotinine measures. Nicotine Tob. Res. 5, 333-339 (2003).
5. Tzatzarakis, M.N. et al. Hair nicotine/cotinine concentrations as a method of monitoring exposure to tobacco smoke among infants and adults. Hum. Exp. Toxicol. 31, 258-265 (2012).
6. Derauf, C., Katz, A.R. & Easa, D. Agreement between maternal self-reported ethanol intake and tobacco use during pregnancy and meconium assays for fatty acid ethyl esters and cotinine. Am. J. Epidemiol. 158, 705-709 (2003).
7. Hamer, M., Ford, T., Stamatakis, E., Dockray, S. & Batty, G.D. Objectively measured secondhand smoke exposure and mental health in children: evidence from the Scottish Health Survey. Arch. Pediatr. Adolesc. Med. 165, 326-331 (2011).
8. Irvine, L. et al. What determines levels of passive smoking in children with asthma? Thorax 52, 766-769 (1997).
9. Collier, A.M. et al. Cotinine elimination and its use as a biomarker in young children involuntarily exposed to environmental tobacco smoke. Indoor Environ. 3, 353-359 (1994).
10. van den Anker, J.N., Schwab, M. & Kearns, G.L. Developmental pharmacokinetics. Handb. Exp. Pharmacol. 205, 51-75 (2011).
11. van den Berg, H., van den Anker, J.N. & Beijnen, J.H. Cytostatic drugs in infants: a review on pharmacokinetic data in infants. Cancer Treat. Rev. 38, 3-26 (2012).
12. Etzel, R.A., Greenberg, R.A., Haley, N.J. & Loda, F.A. Urine cotinine excretion in neonates exposed to tobacco smoke products in utero. J. Pediatr. 107, 146-148 (1985).
13. Dempsey, D., Jacob, P. 3rd & Benowitz, N.L. Nicotine metabolism and elimination kinetics in newborns. Clin. Pharmacol. Ther. 67, 458-465 (2000).
14. Leong, J.W. et al. The elimination half-life of urinary cotinine in children of tobacco-smoking mothers. Pulm. Pharmacol. Ther. 11, 287-290 (1998).
15. Jacob, P. 3rd, Yu, L., Wilson, M. & Benowitz, N.L. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol. Mass Spectrom. 20, 247-252 (1991).
16. Benowitz, N.L., Swan, G.E., Jacob, P. 3rd, Lessov-Schlaggar, C.N. & Tyndale, R.F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther. 80, 457-467 (2006).
17. Schoedel, K.A., Hoffmann, E.B., Rao, Y., Sellers, E.M. & Tyndale, R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14, 615-626 (2004).
18. Pérez-Stable, E.J., Herrera, B., Jacob, P. 3rd & Benowitz, N.L. Nicotine metabolism and intake in black and white smokers. JAMA 280, 152-156 (1998).
19. Al Koudsi, N., Hoffmann, E.B., Assadzadeh, A. & Tyndale, R.F. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur. J. Clin. Pharmacol. 66, 239-251 (2010).
20. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
21. Shimada, T. et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 24, 515-522 (1996).
22. Parkinson, A., Mudra, D.R., Johnson, C., Dwyer, A. & Carroll, K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 199, 193-209 (2004).
23. Hukkanen, J., Jacob, P. 3rd & Benowitz, N.L. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57, 79-115 (2005).
24. Children and secondhand smoke exposure. Excerpts from the Health Consequences of Involuntary Exposure to Tobacco Smoke. A Report of the Surgeon General (U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General, Rockville, MD, 2007).
25. Zhu, A.Z. et al. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol. Biomarkers Prev. 22, 708-718 (2013).
26. Mwenifumbo, J.C. et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum. Mutat. 29, 679-688 (2008).
27. Benowitz, N.L. & Jacob, P. 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56, 483-493 (1994).
28. Dempsey, D. et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76, 64-72 (2004).
29. Ho, M.K. et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin. Pharmacol. Ther. 85, 635-643 (2009).
30. Al Koudsi, N., Ahluwalia, J.S., Lin, S.K., Sellers, E.M. & Tyndale, R.F. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J. 9, 274-282 (2009).
31. Jacob, P. 3rd, Yu, L., Duan, M., Ramos, L., Yturralde, O. & Benowitz, N.L. Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879, 267-276 (2011).
32. Beal, S.L. & Sheiner, L.B. NONMEM User's Guide. (University of California, San Francisco, CA, NONMEM Project Group, 1992).